nach oben

Die Onkologie

Erschienen in:

01.10.2012 | CME Zertifizierte Fortbildung

Perioperative Therapie des lokal fortgeschrittenen Rektumkarzinoms

verfasst von: Prof. Dr. R.-D. Hofheinz, T. Liersch, C. Rödel

Erschienen in: Die Onkologie | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das lokal fortgeschrittene Rektumkarzinom sollte nicht nur operativ, sondern stets multimodal angegangen werden. Die Therapiestrategie hängt vom betroffenen Rektumdrittel ab. In den vergangenen Jahren löste die neoadjuvante Behandlung des lokal fortgeschrittenen Rektumkarzinoms die adjuvante Radiochemotherapie ab. Die vorliegende Arbeit stellt übersichtsartig den gegenwärtigen Stand sowie Perspektiven in der perioperativen Therapie des Rektumkarzinoms dar.

Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 248:1008–1015 CrossRef

Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patient from 22 randomised trials. Lancet 359:1291–1304

Kapiteijn E, Marijnen CAM, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRef

Peeters KC, Marijnen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years. Ann Surg 264:693–701CrossRef

Van Gijn W, Marijnen CAM, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582CrossRef

Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820PubMedCrossRef

Quirke P, Steele R, Monson J et al (2009) Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373:821–828PubMedCrossRef

Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRef

Folkesson J, Birgission H, Påhlman L et al (2005) Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23:5644–5650PubMedCrossRef

10.

Birgisson H, Påhlman L, Gunnarsson U et al (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697–8705PubMedCrossRef

11.

Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858PubMedCrossRef

12.

Birgisson H, Påhlman L, Gunnarsson U et al (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6126PubMedCrossRef

13.

Marijnen CAM, Nagtegaal ID, Klein Kranenbarg E et al (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976–1984PubMed

14.

Påhlman L, Glimelius B (1990) Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Ann Surg 211:187–195PubMedCrossRef

15.

Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933PubMedCrossRef

16.

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

17.

Bonnetain F, Bosset J, Gerard J et al (2012) What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? Eur J Cancer 48(12):1781–1790PubMedCrossRef

18.

Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123PubMedCrossRef

19.

Collette L, Bosset JF, den Dulk M et al (2007) Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4339–4340CrossRef

20.

Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef

21.

Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21:1743–1750PubMedCrossRef

22.

Hofheinz R, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588PubMedCrossRef

23.

Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy with conventionally fractionated radiochemotherapy. Radiother Oncol 72:15–24PubMedCrossRef

24.

Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223PubMedCrossRef

25.

Ngan S, Fisher R, Goldstein D et al (2010) A randomized trial comparing local recurrence rates between short-course and long-course preoperative radiotherapy for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). Abstract 3509. J Clin Oncol [Suppl] 28:152

26.

Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780PubMedCrossRef

27.

Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644PubMedCrossRef

28.

Roh MS, Yothers GA, O’Connell MJ et al (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol [Suppl] 29:Abstract 3503

29.

Rödel C, Liersch T, Becker H (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679–687PubMedCrossRef

30.

Marquardt F, Rödel F, Capalbo G et al (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185:371–378 PubMedCrossRef

31.

MERCURY Study Group (2006) Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333:779CrossRef

32.

Rödel C, Hofheinz R, Liersch T (2012) Rectal cancer: state of the art in 2012. Curr Opin Oncol 24(4):441–447PubMedCrossRef

33.

Maas M, Beets-Tan RGH, Lambregts DMJ et al (2012) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640CrossRef

34.

Fernandez-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging – defined, locally advanced rectal cancer: grupo cáncer de recto 3 study. J Clin Oncol 28:859–865PubMedCrossRef

Titel: Perioperative Therapie des lokal fortgeschrittenen Rektumkarzinoms
verfasst von: Prof. Dr. R.-D. Hofheinz
T. Liersch
C. Rödel
Publikationsdatum: 01.10.2012
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 10/2012
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-012-2271-5

Springer Medizin

Perioperative Therapie des lokal fortgeschrittenen Rektumkarzinoms

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2012

Kontroversen in der adjuvanten System- und Radiotherapie des Endometriumkarzinoms

Endometriumkarzinom

Rezidivierendes Endometriumkarzinom

Kritische Analyse der Internetseiten der Gesellschaft für Biologische Krebsabwehr

Neoadjuvante Radiochemotherapie beim Ösophaguskarzinom

Abiratronacetat – Therapieoption beim metastasierten kastrationsresistenten Prostatakarzinom?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie